Transcriptome Analysis of Epigenetically Modulated Genome Indicates Signature Genes in Manifestation of Type 1 Diabetes and Its Prevention in NOD Mice

PLoS ONE

Volumn 8, Issue 1, 2013, Pages

  Jayaraman, Sundararajan ^a   Patel, Akshay ^a   Jayaraman, Arathi ^a   Patel, Vasu ^a   Holterman, Mark ^a,b   Prabhakar, Bellur ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b UNIVERSITY OF ILLINOIS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACYLTRANSFERASE; CARBOXYPEPTIDASE B; CD74 ANTIGEN; COPPER ZINC SUPEROXIDE DISMUTASE; ELASTASE; PEROXIREDOXIN 6; TRANSCRIPTOME; TRIACYLGLYCEROL LIPASE;

ACUTE DISEASE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARBOXYL ESTER LIPASE GENE; CARBOXYPEPTIDASE B GENE; CD74 GENE; CELA3B GENE; CHROMATIN ASSEMBLY AND DISASSEMBLY; COPPER ZINC SUPEROXIDE DISMUTASE GENE; DOWN REGULATION; EPIGENETICS; ERYTHROPOIESIS; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE REPRESSION; GENOME ANALYSIS; HEMANGIOBLAST; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN SENSITIVITY; LYSOCARDIOPILIN ACYLTRANSFERASE GENE; MOUSE; NONHUMAN; NONOBESE DIABETIC MOUSE; OXIDATION REDUCTION STATE; PANCREAS; PEROXIREDOXIN 6 GENE; PREVENTION STUDY; RNA ANALYSIS; SPLEEN; SPLEEN CELL; T LYMPHOCYTE; TRIACYLGLYCEROL LIPASE GENE; UPREGULATION;

ANIMALS; CHROMATIN ASSEMBLY AND DISASSEMBLY; DIABETES MELLITUS, TYPE 1; DOWN-REGULATION; EPIGENESIS, GENETIC; FEMALE; GENE EXPRESSION PROFILING; GENOMICS; INFLAMMATION; MICE; MICE, INBRED NOD; T-LYMPHOCYTES;

EID: 84873865784     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0055074     Document Type: Article

References (53)

1. Todd JA, (2010) Etiology of type 1 diabetes. Immunity 32: 457-467.
2. Ounissi-Benkalha H, Polychronakos C, (2008) The molecular genetics of type 1. diabetes: new genes and emerging mechanisms. Trends Mol Med 14: 268-275.
3. Ridgway WM, Peterson LB, Todd JA, Rainbow DB, Healy B, et al. (2008) Gene-gene interactions in the NOD mouse model of type 1 diabetes. Adv Immunol 100: 151-157.
4. Chen YG, Silveira PA, Osborne MA, Chapman HD, Serreze DV, (2007) Cellular. expression requirements for inhibition of type 1 diabetes by a dominantly. protective major histocompatibility complex haplotype. Diabetes 56: 424-430.
5. Knip M, (2011) Pathogenesis of type 1 diabetes: implications for incidence. trends. Horm Res Paediatr 76: 57-64.
6. Hyttinen V, Kaprio J, Kinnunen L, Koskenvuo M, Tuomilehto J, (2003) Genetic. liability of type 1 diabetes and the onset age among 22,650 young Finnish twin. pairs: a nationwide follow-up study. Diabetes 252: 1052-1055.
7. Martín-Subero JI, Esteller M, (2011) Profiling epigenetic alterations in disease. Adv Exp Med Biol 711: 162-177.
8. Patel T, Patel V, Singh R, Jayaraman S, (2011) Chromatin remodeling resets the. immune system to protect against autoimmune diabetes in mice. Immunol Cell. Biol 89: 640-649.
9. Jayaraman S, (2011) Epigenetic of autoimmune diabetes. Epigenomics 3: 639-648.
10. Jayaraman S, (2012) Epigenetic mechanisms of metabolic memory in diabetes. Circ Res 110: 1039-1041.
11. Peserico A, Simone C, (2011) Physical and functional HAT/HDAC interplay. regulates protein acetylation balance. J Biomed Biotechnol 2011: 371832.
12. Marks PA, (2010) Histone deacetylase inhibitors: a chemical genetics approach to. understanding cellular functions. Biochim Biophys Acta 1799: 717-725.
13. Hancock WW, (2011) Rationale for HDAC inhibitor therapy in autoimmunity and. transplantation. Handb Exp Pharmacol 206: 103-123.
14. Vukkadapu SS, Belli JM, Ishii K, Jegga AG, Hutton JJ, et al. (2005) Dynamic. interaction between T cell-mediated beta-cell damage and beta-cell repair in the. run up to autoimmune diabetes of the NOD mouse. Physiol Genomics 21: 201-211.
15. Eaves IA, Wicker LS, Ghandour G, Lyons PA, Peterson LB, et al. (2002) Combining mouse congenic strains and microarray gene expression analyses to. study a complex trait: the NOD model of type 1 diabetes. Genome Res 12: 232-243.
16. Eckenrode SE, Ruan Q, Yang P, Zheng W, McIndoe RA, et al. (2004) Gene. expression profiles define a key checkpoint for type 1 diabetes in NOD mice. Diabetes 53: 366-375.
17. Kodama K, Butte AJ, Creusot RJ, Su L, Sheng D, et al. (2008) Tissue- and age-specific changes in gene expression during disease induction and progression in. NOD mice. Clin Immunol 129: 195-201.
18. Irie J, Reck B, Wu Y, Wicker LS, Howlett S, et al. (2008) Genome-wide. microarray expression analysis of CD4+ T cells from nonobese diabetic congenic. mice identifies Cd55 (Daf1) and Acadl as candidate genes for type 1 diabetes. J. Immunol 180: 1071-1079.
19. Regnault B, Osorio Y, Fortea J, Miao D, Eisenbarth G, et al. (2009) Early over. expression of messenger RNA for multiple genes, including insulin, in the. pancreatic lymph nodes of NOD mice is associated with islet autoimmunity. BMC. Med Genomics 2: 63.
20. Rajput A, Singh B, (2004) Gene expression profiling in type 1 diabetes prone. NOD mice immunized with a disease protective autoantigenic peptide. J. Autoimmun 23: 311-321.
21. Christianson SW, Shultz LD, Leiter EH, (1993) Adoptive transfer of diabetes into. immunodeficient NOD-scid/scid mice. Relative contributions of CD4+ and CD8+. T-cells from diabetic versus prediabetic NOD.NON-Thy-1a donors. Diabetes 42: 44-55.
22. Jayaraman S, Patel T, Patel V, Ajani S, Garza R, et al. (2010) Transfusion of. nonobese diabetic mice with allogeneic newborn blood ameliorates autoimmune. diabetes and modifies the expression of selected immune response genes. J. Immunol 184: 3008-3015.
23. Huang da W, Sherman BT, Lempicki RA, (2009) Systematic and integrative. analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 4: 44-57.
24. Makino S, Kunimoto K, Muraoka Y, Mizushima Y, Katagiri K, et al. (1980) Breeding of a non-obese, diabetic strain of mice. Jikken Dobutsu 29: 1-13.
25. Calderon B, Suri A, Unanue ER, (2006) In CD4+ T-cell-induced diabetes,. macrophages are the final effector cells that mediate islet beta-cell killing: studies. from an acute model. Am J Pathol 169: 2137-2147.
26. Hoffman BG, Zavaglia B, Witzsche J, Ruiz de Algara T, Beach M, et al. (2008) Identification of transcripts with enriched expression in the developing and adult. pancreata. Genome Biol 9: R99.
27. Xu H, Foltz L, Sha Y, Madlansacay MR, Cain C, et al. (2001) Cloning and. characterization of human erythroid membrane-associated protein, human. ERMAP. Genomics 76: 2-4.
28. Marques M, Laflamme L, Gervais AL, Gaudreau L, (2010) Reconciling the. positive and negative roles of histone H2A.Z in gene transcription. Epigenetics 5: 267-272.
29. Miyazaki T, Arai S, (2007) Two distinct controls of mitotic cdk1/cyclin B1. activity requisite for cell growth prior to cell division. Cell Cycle 6: 1419-1425.
30. Azad MB, Chen Y, Gibson SB, (2009) Regulation of autophagy by reactive. oxygen species (ROS): implications for cancer progression and treatment. Antioxid Redox Signal 11: 777-790.
31. Wang C, Faloon PW, Tan Z, Lv Y, Zhang P, et al. (2007) Mouse lysocardiolipin. acyltransferase controls the development of hematopoietic and endothelial. lineages during in vitro embryonic stem-cell differentiation. Blood 110: 3601-3609.
32. Giacco F, Brownlee M, (2010) Oxidative stress and diabetic complications. Circ. Res 107: 1058-1070.
33. Borghese F, Clanchy FI, (2011) CD74: an emerging opportunity as a therapeutic. target in cancer and autoimmune disease. Expert Opin Ther Targets 15: 237-251.
34. Rojas-Espinosa O, Arce-Paredez P, Dannenberg AM, Kamaenetz RL, (1975) Macrophage esterase: identification, purification and properties of a. chymotrypsin-like esterase from lung that hydrolyses and transfers nonpolar. amino acid esters. Biochim Biophys Acta 403: 161-179.
35. Weinrauch Y, Drujan D, Shapiro SD, Weiss J, Zychlinsky A, (2002) Neutrophil. elastase targets virulence factors of enterobacteria. Nature 417: 91-94.
36. Korkmaz B, Horwitz MS, Jenne DE, Gauthier F, (2010) Neutrophil elastase,. proteinase 3, and cathepsin G as therapeutic targets in human diseases. Pharmacol. Rev 62: 726-759.
37. Lee LF, Lih CJ, Huang CJ, Cao T, Cohen SN, et al. (2008) Genomic expression. profiling of TNF-alpha-treated BDC2.5 diabetogenic CD4+ T cells. Proc Natl. Acad Sci USA 105: 10107-10112.
38. Devaraj S, Dasu MR, Rockwood J, Winter W, Griffen SC, et al. (2008) Increased. toll-like receptor (TLR) 2 and TLR4 expression in monocytes from patients with. type 1 diabetes: further evidence of a proinflammatory state. J Clin Endocrinol. Metab 93: 578-583.
39. Cantor J, Haskins K, (2005) Effector function of diabetogenic CD4 Th1 T cell. clones: a central role for TNF-alpha. J Immunol 175: 7738-7745.
40. Pakala SV, Kurrer MO, Katz JD, (1997) T helper 2 (Th2) T cells induce acute. pancreatitis and diabetes in immune-compromised nonobese diabetic (NOD). mice. J Exp Med 186: 299-306.
41. Bending D, De la Peña H, Veldhoen M, Phillips JM, Uyttenhove C, et al. (2009) Highly purified Th17 cells from BDC2.5NOD mice convert into Th1-like cells. in NOD/SCID recipient mice. J Clin Invest 119: 565-572.
42. Martin-Orozco N, Chung Y, Chang SH, Wang YH, Dong C, (2009) Th17 cells. promote pancreatic inflammation but only induce diabetes efficiently in. lymphopenic hosts after conversion into Th1 cells. Eur J Immunol 39: 216-224.
43. Serreze DV, Chapman HD, Post CM, Johnson EA, Suarez-Pinzon WL, et al. (2001) Th1 to Th2 cytokine shifts in nonobese diabetic mice: sometimes an. outcome, rather than the cause, of diabetes resistance elicited by. immunostimulation. J Immunol 166: 1352-1359.
44. Kanagawa O, Xu G, Tevaarwerk A, Vaupel BA, (2000) Protection of nonobese. diabetic mice from diabetes by gene(s) closely linked to IFN-gamma receptor. loci. J Immunol 164: 3919-3923.
45. Sobel DO, Han J, Williams J, Yoon JW, Jun HS, et al. (2002) Gamma interferon. paradoxically inhibits the development of diabetes in the NOD mouse. J. Autoimmun 19: 129-137.
46. Bloom BR, Bennett B, Oettgen HF, McLean EP, Old LJ, (1969) Demonstration of. delayed hypersensitivity to soluble antigens of chemically induced tumors by. inhibition of macrophage migration. Proc Natl Acad Sci USA 64: 1176-1180.
47. Jayaraman S, Muthukkaruppan VR, (1977) In vitro correlate of transplantation. immunity: spleen cell migration inhibition in the lizard, Calotes Versicolor. Dev. Comp Immunol 1: 133-143.
48. Jayaraman S, Mohan R, Muthukkaruppan VR, (1979) Relationship between. migration inhibition and plaque-forming cell responses to sheep erythrocytes in. the teleost, Tilapia mossambica. Dev Comp Immunol 3: 67-75.
49. Kleemann R, Bucala R, (2010) Macrophage migration inhibitory factor: critical. role in obesity, insulin resistance, and associated comorbidities. Mediators. Inflamm 2010: 610479.
50. Tong C, Morrison A, Yan X, Zhao P, Yeung ED, et al. (2010) Macrophage. migration inhibitory factor deficiency augments cardiac dysfunction in Type 1. diabetic murine cardiomyocytes. J Diabetes 2: 267-274.
51. Baxter AG, Mandel TE, (1991) Hemolytic anemia in non-obese diabetic mice. Eur J Immunol 21: 2051-2055.
52. Mestas J, Hughes CC, (2004) Of mice and not men: differences between mouse. and human immunology. J Immunol 172: 2731-2738.
53. Vanhaecke T, Papeleu P, Elaut G, Rogiers V, (2004) Trichostatin A-like. hydroxamate histone deacetylase inhibitors as therapeutic agents: toxicological. point of view. Curr Med Chem 11: 1629-1643.